Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance

Pediatric Blood and Cancer

Volumn 61, Issue 9, 2014, Pages 1570-1577

  Monsma, David J ^a   Cherba, David M ^a   Richardson, Patrick J ^a   Vance, Sean ^a   Rangarajan, Sanjeet ^a   Dylewski, Dawna ^a   Eugster, Emily ^a   Scott, Stephanie B ^a   Beuschel, Nicole L ^a   Davidson, Paula J ^a   Axtell, Richard ^b   Mitchell, Deanna ^b   Lester, Eric P ^c   Junewick, Joseph J ^d   Webb, Craig P ^e   Monks, Noel R ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^c Oncology Care Associates PLLC   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e NuMedii Inc   (United States)

Author keywords

Drug efficacy; Drug prediction; Gene expression profiling; PDX; Precision medicine; Rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; IFOSFAMIDE; LAPATINIB; PACLITAXEL; PANITUMUMAB; RAPAMYCIN; SORAFENIB; TEMSIROLIMUS; TIAZOFURIN; VALPROIC ACID;

ADULT; ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CASE REPORT; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION PROFILING; HEALTH CARE QUALITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR BIOPSY; XENOGRAFT;

DRUG EFFICACY; DRUG PREDICTION; GENE EXPRESSION PROFILING; PDX; PRECISION MEDICINE; RHABDOMYOSARCOMA;

ADULT; ALGORITHMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLUREA COMPOUNDS; PYRIMIDINES; RHABDOMYOSARCOMA, ALVEOLAR; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904411006     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25039     Document Type: Article

References (56)

1. Gasparini G, Longo R. The paradigm of personalized therapy in oncology. Expert Opin Ther Targets 2012; 16:S7-S16.
2. Awada A, Vandone AM, Aftimos P. Personalized management of patients with solid cancers: Moving from patient characteristics to tumor biology. Curr Opin Oncol 2012; 24:297-304.
3. Blay JY, Le Cesne A, Cassier PA, et al. Gastrointestinal stromal tumors (GIST): A rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med 2012; 13:357-367.
4. Marisa L, de Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med 2013; 10:e1001453.
5. Yap TA, Workman P. Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012; 52:549-573.
6. McLeod HL. Cancer pharmacogenomics: Early promise, but concerted effort needed. Science 2013; 339:1563-1566.
7. Duffy MJ, Crown J. Companion biomarkers: Paving the pathway to personalized treatment for cancer. Clin Chem 2013; 59:1447-1456.
8. Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma Study-I-A Final Report. Cancer 1988; 61:209-220.
9. Casanova M, Ferrari A. Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opin Pharmaco 2011; 12:517-531.
10. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999; 17:3487-3493.
11. Raney RB, Asmar L, Newton WA, et al. Ewing's sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol 1997; 15:574-582.
12. Saulnier Sholler GL, Ferguson W, Bergendahl G, et al. A pilot trial testing the feasibility of using molecular-guided therapy in patients with recurrent neuroblastoma. J Cancer Ther 2012; 3:602-612.
13. Monks NR, Cherba DM, Kamerling SG, et al. A multi-site feasibility study for personalized medicine in canines with Osteosarcoma. J Transl Med 2013; 11:158.
14. Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010; 16:974-975.
15. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9:338-350.
16. Siolas D, Hannon GJ. Patient derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res 2013; 73:5315-5319.
17. Merlino G, Flaherty K, Acquavella N, et al. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res 2013; 26:E8-E14.
18. Garber K. From human to mouse and back: "Tumorgraft" models surge in popularity. J Natl Cancer Inst 2009; 101:6-8.
19. Monsma DJ, Monks NR, Cherba DM, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 2012; 10:125.
20. DeRose YS, Wang G, Lin YC, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17:1514-1520.
21. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10:3-8.
22. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 19:1311-1316.
23. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 2010; 28:4658-4663.
24. Tolcher A, Papadopolous K, Patniak A, et al. Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) "trap" FP-1039 (FGF R1: Fc) in patients with advanced malignancies. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Volume 8. Berlin: European Journal of Cancer Supplements. 2010; p 121.
25. Knox C, Law V, Jewison T, et al. DrugBank 3.0: A comprehensive resource for "omics" research on drugs. Nucleic Acids Res 2011; 39:D1035-D1041.
26. Von Hoff DD, Stephenson JJ, Jr., Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877-4883.
27. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007; 67:3171-3176.
28. Lamb J, Crawford ED, Peck D, et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313:1929-1935.
29. Dezso Z, Nikolsky Y, Nikolskaya T, et al. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 2009; 3:36.
30. Wolf J, LoRusso PM, Camidge RD, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Volume 72. Chicago. IL: Cancer Research. 2012.
31. Fuchs J, Wenderoth M, von Schweinitz D, et al. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 1998; 83:2400-2407.
32. Izbicka E, Campos D, Marty J, et al. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res 2006; 26:1983-1988.
33. Chang AY, Boros L, Garrow GC, et al. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: A dose-escalation study. Semin Oncol 1996; 23:74-77.
34. Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93:1388-1394.
35. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20:5736-5746.
36. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66:6936-6946.
37. Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 2:1118-1133.
38. Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70:6497-6508.
39. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-255.
40. Rose A, Grandoch M, vom Dorp F, et al. Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol 2010; 160:1690-1698.
41. Crose LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma 2011; 2011:756982.
42. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64:5539-5545.
43. Monks NR, Liu S, Xu Y, et al. Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol Cancer Ther 2007; 6:587-598.
44. Crouch GD, Kalebic T, Tsokos M, et al. Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. Exp Cell Res 1993; 204:210-216.
45. DuBois SG, Krailo MD, Lessnick SL, et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52:324-327.
46. Houghton PJ, Morton CL, Kang M, et al. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55:1224-1226.
47. Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013; 2:e00747.
48. Blandford MC, Barr FG, Lynch JC, et al. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the Children's Oncology Group. Pediatr Blood Cancer 2006; 46:329-338.
49. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-1940.
50. van Gaal JC, Roeffen MH, Flucke UE, et al. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: A rational choice. Eur J Cancer 2013; 49:3462-3470.
51. Renshaw J, Taylor KR, Bishop R, et al. Dual blockade of the PI3K/AKT/mTOR (AZD 8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res 2013; 19:5940-5951.
52. Yamamoto Y, Fukuda K, Fuchimoto Y, et al. Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro. Oncol Rep 2013; 30:1081-1086.
53. Hu K, Lee C, Qiu D, et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009; 8:3024-3035.
54. Annavarapu SR, Cialfi S, Dominici C, et al. Characterization of Wnt/beta-catenin signaling in rhabdomyosarcoma. Lab Invest 2013; 93:1090-1099.
55. Nielsen TO, West RB. Translating gene expression into clinical care: Sarcomas as a paradigm. J Clin Oncol 2010; 28:1796-1805.
56. Sokolowski E, Turina CB, Kikuchi K, et al. Proof-of-concept rare cancers in drug development: The case for rhabdomyosarcoma. Oncogene 2013; DOI:10.1038/onc.2013.129